Lantheus Holdings Inc (LNTH) Shares Sold by Royce & Associates LP
Royce & Associates LP reduced its stake in Lantheus Holdings Inc (NASDAQ:LNTH) by 26.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 203,168 shares of the medical equipment provider’s stock after selling 74,214 shares during the period. Royce & Associates LP owned 0.54% of Lantheus worth $3,616,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of Lantheus by 7.0% during the first quarter. Vanguard Group Inc. now owns 788,396 shares of the medical equipment provider’s stock worth $9,855,000 after acquiring an additional 51,590 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of Lantheus during the first quarter worth about $3,646,000. Russell Investments Group Ltd. increased its position in shares of Lantheus by 57.9% during the second quarter. Russell Investments Group Ltd. now owns 280,653 shares of the medical equipment provider’s stock worth $4,954,000 after acquiring an additional 102,922 shares in the last quarter. Municipal Employees Retirement System of Michigan bought a new stake in shares of Lantheus during the second quarter worth about $107,000. Finally, Great West Life Assurance Co. Can bought a new stake in shares of Lantheus during the second quarter worth about $684,000. 91.91% of the stock is owned by hedge funds and other institutional investors.
In related news, CFO John W. Crowley sold 6,755 shares of the business’s stock in a transaction dated Friday, October 13th. The shares were sold at an average price of $18.41, for a total transaction of $124,359.55. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Timothy G. Healey sold 11,314 shares of the business’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $21.51, for a total transaction of $243,364.14. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 29,986 shares of company stock worth $625,488. 2.30% of the stock is owned by corporate insiders.
Lantheus Holdings Inc (NASDAQ LNTH) opened at $20.35 on Tuesday. Lantheus Holdings Inc has a twelve month low of $7.95 and a twelve month high of $24.10. The firm has a market cap of $738.87, a PE ratio of 17.59, a P/E/G ratio of 1.56 and a beta of 0.94. The company has a current ratio of 2.96, a quick ratio of 2.46 and a debt-to-equity ratio of -3.41.
Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.04. Lantheus had a net margin of 9.59% and a negative return on equity of 46.45%. The business had revenue of $79.94 million for the quarter, compared to analysts’ expectations of $77.18 million. During the same period in the previous year, the company earned $0.15 earnings per share. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. analysts predict that Lantheus Holdings Inc will post 1.05 EPS for the current year.
WARNING: “Lantheus Holdings Inc (LNTH) Shares Sold by Royce & Associates LP” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/lantheus-holdings-inc-lnth-shares-sold-by-royce-associates-lp/1772771.html.
Lantheus Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.